Advertisement

HIV-Infekt pp 301-307 | Cite as

Antiretrovirale Salvage-Therapie mit zwei Proteaseinhibitoren bei HIV-infizierten Kindern: Vergleich von Kombinations-therapien mit Ritonavir/Saquinavir und Nelfinavir/Saquinavir

  • F. Hoffmann
  • G. Notheis
  • U. Wintergerst
  • J. Eberle
  • L. Gürtler
  • B. H. Belohradsky
Conference paper

Zusammenfassung

Aktuelle Richtlinien [1, 2, 8, 12] für die Behandlung der HIV-Infektion empfehlen, die Viruslast unter die Nachweisgrenze momentan verfügbarer Assays zu senken. Dieser Durchbruch in der antiretroviralen Therapie wurde durch die Einführung von Kombinationstherapien mit Proteaseinhibitoren erreicht. Antiretrovirale Dreifachkombinationen bestehend aus 2 Nukleosidanaloga (NRTI) und 1 Proteaseinhibitor (PI) führten bei einem großen Anteil der Patienten zu einer Senkung der Viruslast unter die Nachweisgrenze [3, 4]. Durch suboptimale Suppression der HIV-Replikation oder Compliance-Probleme kann es zur Entwicklung von Resistenzen und damit verbunden zu einem Wiederanstieg der Viruslast mit der Gefahr einer Krankheitsprogression kommen. Für diese Patienten mit Versagen einer PI-Vortherapie empfehlen aktuelle Therapierichtlinien den Einsatz von Kombinationsregimen bestehend aus 2 PIs und 2 NRTIs [1,2].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Carpenter CC, Fischi M, Hammer SM et al. (1998) Antiretroviral therapy for HIV-infection in 1998. Updated recommendations of the International AIDS Society-USA Panel. JAMA 280: 78–86PubMedCrossRefGoogle Scholar
  2. 2.
    Department of Health and Human Services (1998) Panel on Clinical Practices for Treatment of HIV Infection: Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Document 31 March 1998 [Internet: http://www.hivatis.org]Google Scholar
  3. 3.
    Gulick RM, Mellors JW, Havlir D et al. (1997) Treatment with indinavir, zidovudine, and lamivudi- ne in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734–789PubMedCrossRefGoogle Scholar
  4. 4.
    Hammer SM, Squires KE, Hughes MD et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337: 725–733PubMedCrossRefGoogle Scholar
  5. 5.
    Hammond J, Calef C, Larder B, Schinazi R, Mellors J (1998) Mutations in retroviral genes associated with drug resistance. From: Human Retroviruses and AIDS. http://hiv-web.lanl.gov/HTML/ 98compendium.htmlGoogle Scholar
  6. 6.
    Harrigan PR, Dong W, Weber AE et al. (1998) Clinical failure is associated with highly mutated RT and Protease. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 24.–27. 9. 98 [abstract I-115]Google Scholar
  7. 7.
    Kaufmann GR, Duncombe C, Cunningham P et al. (1998) Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS 12: 1625–1630PubMedCrossRefGoogle Scholar
  8. 8.
    Kempf DJ, Rode RA, Xu Y et al. (1998) The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-i RNA at the nadir. AIDS 12: F9 - F14PubMedCrossRefGoogle Scholar
  9. 9.
    Merry C, Barry MG, Mulcahy F et al. (1997) Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11:F29‐F33PubMedCrossRefGoogle Scholar
  10. 10.
    Merry C, Barry MG, Mulcahy F, Halifax KL, Back DJ (1997) Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 11:F117‐Fi20PubMedCrossRefGoogle Scholar
  11. 11.
    Montaner JSM, Jahnke N, Hogg R et al. (1998) Multi-drug rescue therapy (MDRT) for HIV-infected individuals with prior virologie failure to multiple regimens: preliminary results. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 24.–27. 9. 98 [abstract I‐201]Google Scholar
  12. 12.
    Raboud JM, Montaner JS, Conway B et al. (1998) Suppression of plasma viral load below 20 copies/ml is required to achieve long-term response to therapy. AIDS 12: 1619–1624PubMedCrossRefGoogle Scholar
  13. 13.
    Weverling GJ, Lange JMA, Jurriaans S et al. (1998) Alternative multidrug regimen provides improved suppressiom of HIV‐i replication over triple therapy. AIDS 12:F117‐F122PubMedCrossRefGoogle Scholar
  14. 14.
    Wintergerst U, Hoffmann F, Söder B et al. (1998) Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficieny virus. Pediatr Infect Dis J 17: 495–499PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • F. Hoffmann
  • G. Notheis
  • U. Wintergerst
  • J. Eberle
  • L. Gürtler
  • B. H. Belohradsky

There are no affiliations available

Personalised recommendations